Skip to search formSkip to main contentSkip to account menu

PAT-1102

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Hydroxamic AcidsTriazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
AIM Histone deacetylase (HDAC) inhibitors are a class of drugs that modulate transcriptional activity in cells and are known to… 
2013
2013
Abstract 2051: PAT-1102, a novel HDAC inhibitor exhibits potent anti-tumor efficacy in patient-derived refractory solid tumors.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Histone deacetylases (HDAC) have been shown to be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)